Background: Patients with amnestic mild cognitive impairment (MCI) represent an important clinical group as they are at increased risk of developing Alzheimer disease (AD). 11 C-PIB PET is an in vivo marker of brain amyloid load.
The pathologic hallmarks of AD are extracellular beta-amyloid (A␤) plaques and intraneuronal neurofibrillary tangles. Neuropathologic studies on postmortem brain tissue have reported an increasing prevalence of AD pathology in elderly nondemented subjects, amnestic MCI, and probable AD cases. However, a difficulty with autopsy studies is that inevitably no longitudinal outcome data are available. PET now provides an opportunity to correlate in vivo the presence of brain amyloid deposition with outcome in health and MCI, as this can be detected using the thioflavin-based radiotracer Pittsburgh compound B (PIB). 10 Long-term follow-up studies have the potential to determine the utility of 11 C-PIB PET in predicting who will develop AD. 11 Furthermore, studies suggest that 11 C-PIB may be more sensitive than CSF A␤ and tau measurements for detecting an early AD process in MCI. 12 In this study, we sought to determine the rates at which subjects with amnestic MCI with and without an increased amyloid load (as assessed by 11 C-PIB PET) converted to clinically probable AD over 1 to 3 years and to compare the levels of amyloid deposition between those PIB-positive subjects with MCI who were faster and slower converters.
METHODS Subjects. Thirty-one subjects fulfilling the Petersen et al. criteria 3 for amnestic MCI were studied. Fourteen of these subjects with MCI (mean age 66.6 years: SD 9.6) were recruited from UK Hospitals (Imperial College Healthcare NHS Trust [London], The National Hospital for Neurology and Neurosurgery [London], St. Margaret's Hospital [Epping, and Victoria Hospital [Swindon] ). The remaining 17 subjects (mean age 71.7 years: SD 5.3) were recruited from the University Hospital of Turku, Finland. The demographic data of subjects with MCI and controls according to center are presented in table e-1 on the Neurology ® Web site at www.neurology.org. The majority of subjects with MCI enrolled to the study were newly diagnosed cases. All subjects with MCI had a neurologic examination, neuropsychological assessment, and routine blood analysis. The clinical criteria for MCI were operationalized as 1) subjective memory complaint by the patient, preferably corroborated by an informant, 2) objective memory impairment as assessed by performance below age-matched normals on at least one neuropsychological measure of memory, 3) relatively normal performance in other cognitive domains, 4) intact activities of daily living, and 5) no dementia. A strict cutoff score was not applied for the definition of objective memory impairment. However, the appropriate age-matched normative values were used when determining evidence for objective memory impairment on performance on tests of memory including word list savings (%) of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 13 test battery, Wechsler Memory Scale-Revised (WMS-R) 14 (Turku), Alzheimer's Disease Assessment Scale (ADAS) word list learning with delayed recall, 15 California Verbal Learning Test (CVLT), 16 and immediate and delayed recall of a modified complex figure 17 (London).
Twenty-seven of the 31 subjects had their 11 C-PIB PET and MRI at baseline as part of previous studies comparing 11 C-PIB uptake in MCI and controls. 18 Clinical follow-up. The subjects with MCI were clinically followed for periods of 1 to 3 years after their baseline 11 C-PIB PET. All subjects with MCI who had a PIB PET scan at baseline were reviewed at follow-up. Over this follow-up period, there was either no change in their diagnosis and they still fulfilled criteria for MCI (nonconverters) or their symptoms and clinical performance declined to the extent that they fulfilled National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria 22 for a diagnosis of probable AD (converters).
Brain imaging. MRI. All subjects had T1-weighted volumetric MRI to allow structure-function coregistration with 11 C-PIB PET images. Additionally, T2-weighted MRI was performed to exclude structural lesions. 11 C-PIB PET. UK. All subjects with MCI and healthy volunteers were scanned at the Cyclotron Building, Hammersmith Hospital, London, using a Siemens ECAT EXACT HRϩ camera in 3-dimensional acquisition mode. 23 Prior to the injection of 11 C-PIB, a 10-minute transmission scan was performed to measure tissue attenuation of 511 keV ␥-radiation. The 11 C-PIB PET protocol has been previously described. 20 Subjects with MCI received 367 Ϯ 25 MBq 11 C-PIB injected IV, followed by a 90-minute dynamic emission scan. 11 C-PIB was manufactured and supplied by GE Healthcare, Hammersmith Imanet, UK. Turku. Subjects with MCI and healthy volunteers were scanned with a GE Advance camera, using a previously described protocol. 24 The dynamic PET emission scans were acquired in 3-dimensional mode during a 90-minute period and transmission scans performed to measure tissue attenuation of 511 keV ␥-radiation. 11 C-PIB was manufactured by Turku PET Centre, Finland. The mean injected dose of 11 C-PIB for subjects with MCI was 487 Ϯ 44 MBq.
Image analysis. Creation of 11 C-PIB target region:
Cerebellar cortex ratio images. All UK and Turku PIB PET images were analyzed at a central site (Cyclotron Building, Hammersmith Hospital, London), by a standardized method of analysis previously described. 20 In summary, using the cerebellar cortex as a reference region, we produced parametric ratio images of PIB retention by normalizing the 60-minute to 90-minute (late) summation images to the mean cerebellar cortical uptake value over this same period. Image analysis was performed using Analyze (Mayo Clinic, MN) and Statistical Parametric Mapping software (SPM99; Wellcome Department of Imaging Neuroscience, University College London). Using individual T1weighted MRIs as a template, each parametric image was normalized into Montreal Neurological Institute (MNI) space and PIB retention assessed by both region of interest (ROI) analysis and statistical parametric mapping (SPM).
Statistical analysis. ROI analysis.
Using an in-house probabilistic brain atlas 25 that creates an individualized anatomic template for each subject, we quantified average PIB retention (left and right) in the anterior cingulate, posterior cingulate, frontal, temporal, parietal, and occipital cortex.
All PIB PET dynamic data (London and Turku) were acquired over 90 minutes and expressed as a 60-minute to 90minute target region: cerebellar ratio of PIB retention, minimizing between-site variability by using an internal reference for each subject. Individually, PIB retention ratio values for each subject with MCI were compared to that of the control mean of their scanning site. We considered PIB binding to be increased in each subject with MCI if Ն2 SD greater than the control mean in all 6 of our predefined ROIs.
Increases in PIB retention in the subjects with MCI relative to their control mean were described as a percentage change. Additionally, we used univariate analysis of variance to detect significant differences in regional PIB binding between MCI and control groups, with the 2 different PET centers being set as fixed factors, and using the p plot method and Hochberg correction to control for multiple comparisons. 26 Using these methods, we also compared PIB retention between MCI converters and nonconverters. Finally, we considered PIB-positive subjects with MCI alone and compared differences in regional PIB binding in the PIB-positive faster converters (conversion to AD within 1 year follow-up) to that in the combined group of PIB-positive slower converters (conversion to AD after more than 1 year) and PIB-positive nonconverters (no conversion to date).
A secondary statistical analysis was performed using age as a covariate, the rest of the analysis being otherwise identical. APOE 4 status. APOE status was available in 17 of our 31 subjects with MCI (Turku cohort). For these subjects, we ap-plied binomial chi-square tests to assess the relationship between APOE 4 status and rates of conversion.
Statistical tests were performed using SPSS for Windows 14.0 statistical software.
SPM.
In addition to ROI analysis, we also interrogated PIB ratio images with SPM in order to localize at a voxel level clusters of significant differences in mean PIB retention between MCI converters and nonconverters, and between PIB-positive faster and PIB-positive slower and nonconverters. We smoothed our normalized PIB ratio images using a Gaussian kernel of 6 mm. Between-group comparisons were made using a voxel threshold of p Ͻ 0.0001 (converters vs nonconverters) and p Ͻ 0.01 (faster converters vs slower and nonconverters), with an extent threshold of 200 voxels. We did not apply grand mean or proportional scaling to the data, and the 2 scanning sites were considered as covariates when performing the analysis. Any resulting clusters with a corrected p value of Ͻ0.05 are reported.
RESULTS ROI analysis. Baseline. Subjects with MCI and
controls. The mean PIB retention ratio values in the subjects with MCI are shown in table 1. When compared to controls, the subjects with MCI showed a 41% increase in PIB retention in the anterior cingulate ( p Ͻ 0.01), 40% increase in the posterior cingulate ( p Ͻ 0.01), 37% increase in the frontal cortex ( p Ͻ 0.01), 36% increase in the parietal cortex ( p Ͻ 0.01), 28% increase in the temporal cortex ( p Ͻ 0.01), and 20% increase in the occipital cortex ( p Ͻ 0.01). Significance levels remained unchanged after applying age as a covariate.
Individually, 17 of 31 (55%) subjects with MCI had significantly increased PIB retention values compared to controls at baseline in all ROIs. Two other subjects with MCI demonstrated isolated increases in PIB retention in the anterior cingulate and frontal cortex (see Discussion).
Follow-up. Subjects with MCI. During a 12-36-month follow-up period after their baseline PIB PET scan, 15 (4 London, 11 Turku) of the 31 subjects with MCI (48%) clinically converted to AD. Fourteen of these 15 converters were PIB-positive at baseline, making the percentage conversion rate in the PIBpositive subgroup 82% (14 out of 17) over this same follow-up period. One converter had small increases in PIB retention in the anterior cingulate and frontal cortex alone. When assessed by center, the percentage conversion rate in the PIB-positive subgroup was 57% for London (4 out of 7) and 100% for Turku (all 10 PIB-positive subjects with MCI converted to AD).
MCI converters vs nonconverters. Compared to MCI nonconverters, the converters showed higher PIB retention in all cortical brain regions ( p Ͻ 0.01 both with and without correction for age) (table 1) .
MCI PIB-positive faster vs combined PIB-positive slower and nonconverters. As a group, the PIB-positive faster converters had higher PIB retention values compared to the combined subgroup of slower and nonconverters in the anterior cingulate (p ϭ 0.027) and frontal cortex (p ϭ 0.031), although this did not survive correction for multiple comparisons (table 2). 
MCI PIB-positive faster converters vs combined PIB-
positive slower and nonconverters. SPM confirmed the findings from ROI analysis; significantly higher PIB binding was detected in the PIB-positive faster converters compared to the combined group of PIBpositive slower and nonconverters and was most marked in the superior frontal cortex. SPM additionally localized significantly increased 11 C-PIB binding in the temporal cortex of faster compared to slower and nonconverters ( figure 3 ).
DISCUSSION
In this 11 C-PIB PET study, we found that 17 of 31 (55%) subjects with amnestic MCI had significantly increased PIB retention compared to controls. This finding is consistent with the prevalence of amyloid deposition previously reported in 11 C-PIB PET studies in subjects with amnestic MCI. 27, 28 When compared to nonconverters, MCI converters were found to have significantly increased PIB retention in all designated ROIs. Individually, 15 of 31 subjects with MCI (48% of total) converted to a diagnosis of AD during a follow-up period which ranged from 1 to 3 years (2.9 years Ϯ 0.5 in converters; 2.5 years Ϯ 0.7 in nonconverters). Fourteen of these 15 subjects were PIBpositive at baseline. A recent PET study 11 reported that one third of their 21 subjects with MCI, all PIB positive, converted to AD over 8 months. Only 12 of 21 of their subjects with MCI were categorized as amnestic, but all 7 converters were of the amnestic subtype. Eighty-two percent of our PIB-positive amnestic subjects with MCI converted to a diagnosis of AD over a 3-year follow-up period. The conversion rates to AD in PIB-positive compared to PIB-negative subjects with MCI in these 2 studies suggest that in vivo detection of amyloid deposition may provide useful prognostic information with respect to stratifying those amnestic patients with MCI at increased risk of dementia. In contrast to population-based studies in MCI, where some subjects recover, 29 all our subjects with MCI continue to have evidence of memory impairment.
A recent neuropathologic study in subjects with MCI reported that the majority had "prodromal or incipient" AD with diffuse neocortical amyloid deposits and frequent medial temporal lobe neurofibrillary tangles, albeit at insufficient levels to fulfill AD criteria. 1 One way to investigate the pathologic changes present in the earliest phase of AD is to study familial AD mutation carriers. Recently, 11 C-PIB PET studies have been performed in such patients and interestingly point mutations 30 and deletions 31 in both symptomatic and asymptomatic carriers of the presenilin-1 gene and duplication of the amyloid pre-cursor protein locus 32 have all been shown to lead to increases in 11 C-PIB uptake, which are predominantly striatal-a pattern distinct from that seen in sporadic AD. Follow-up studies will reveal how the pattern of 11 C-PIB uptake will evolve with the development and progression of clinical symptoms.
In a longitudinal 11 C-PIB PET follow-up of patients with early AD over 2 years, 33 researchers found that the amyloid load in their AD group remained relatively stable. This finding, in addition to PIB PET findings in familial AD cases, suggests that amyloid deposition occurs early in the clinical evolution of AD. It is less clear, however, at what stage amyloid deposition, as detectable by PIB PET, plateaus in any given patient during the clinical transition from MCI to AD.
We found that our PIB-positive more rapid converters had a significantly increased amyloid burden in the anterior cingulate and frontal cortices compared to our PIB-positive slower and nonconverters that fell within the reported range for patients with AD. 20 This suggests that our MCI faster converters may have already reached their amyloid load plateau. While the slower converters had lower levels of amyloid load, these were also within the reported Alzheimer range, and so may represent a "prodromal or incipient" AD phase at the time of scanning.
Alternatively, some separate factor, for example, APOE status or levels of education, 34 may have influenced the difference in rates of conversion and amyloid burden between the 2 groups. Postmortem studies have shown correlations between the presence of an APOE 4 allele and higher A␤ burden in the brains of patients with sporadic AD. 35, 36 A separate study found that levels of A␤ protein deposition varied according to APOE genotype in elderly subjects both with and without dementia, the highest mean values being associated with the presence of at least one 4 allele. 37 A limitation of this current study is that we did not possess APOE 4 status in all of our subjects with MCI, given that a previous 11 C-PIB PET study in AD, examining the association between clinical severity and amyloid plaque load, reported APOE 4 status to be a possible confounding factor. 38 Here, the authors found an association between dementia severity and 11 C-PIB uptake in AD, ROI analysis showing that individuals with more severe dementia had higher 11 C-PIB uptake bilaterally in the frontal and anterior cingulate cortices and putamina. In our cohort, we found an association between APOE 4 status in our PIB-positive subjects with MCI and rate of clinical conversion to AD, with all faster converters being APOE 4 carriers.
Two subjects showed small selective increases in PIB retention in the anterior cingulate and frontal cortex alone. Patient 1 is an 80-year-old woman whose clinical diagnosis during a 3-year follow-up period has remained MCI. Patient 2 is a 64-year old man who at his 3-year follow-up had clinically converted to AD. A number of 11 C-PIB PET studies have demonstrated increased amyloid deposition with or without evidence of objective memory impairment in asymptomatic elderly controls. 39, 40 However, given their documented memory impairment, it is more likely that the focally increased amyloid burden in patient 1 represents preclinical AD. Further clinical and PIB PET follow-up in this patient will determine the significance of this increased amyloid burden, while further PIB PET follow-up in all our subjects with MCI will allow us to follow, in vivo, the progression over time in amyloid deposition and its relevance to the clinical conversion to AD.
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